Compare DexCom, Inc. (DXCM) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? DexCom, Inc. trades at $83.67 (market cap $31.86B), while Vanguard Dividend Appreciation Index Fund ETF trades at $238.12 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 4.2× DexCom, Inc.'s market cap, and DexCom, Inc. is more actively traded (3,607,070 versus 1,287,188). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vanguard Dividend Appreciation Index Fund ETF for 133 Days on average.
| DXCM | VIG | |
|---|---|---|
Market Cap | $31.86B | $132.40B |
Volume | 3,607,070 | 1,287,188 |
Sector | Health | — |
52-Week High | $92.34 | $246.61 |
52-Week Low | $54.84 | $210.70 |
Typical Hold Time | 62 Days | 133 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
VIG trades at $237.99, up 0.42% with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights its 7.5% quarterly dividend increase and long-term return potential averaging 10% annually since inception.
Outlook remains positive for investors seeking dividend growth with moderate risk, though the low current yield and exclusion of high-yield stocks present trade-offs. Key risks include market volatility and the ETF's specific eligibility rules limiting certain holdings. The growth-oriented strategy appeals to long-term investors prioritizing increasing income over current yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
